John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses previous research with anti-HER2 TKIs in HER2-positive breast cancer, expanded on key follow-up data from this phase 2 trial, and emphasized the importance of continued investigation into this underutilized combination.
The PIM1 kinase inhibitor TP-3654 was well tolerated and showcased preliminary signs of activity, including spleen volume reduction, symptom improvement, and broad cytokine reduction, in patients with myelofibrosis who were previously treated with or were ineligible for a JAK inhibitor.
Amandeep Salhotra, MD, provides insight on the data with Orca-Q shared during the 2022 ASH Annual Meeting.
Press Release
The Association of Community Cancer Centers is announcing the release of a new tool intended to facilitate education and adoption of new clinical and technological advancements in diagnosis, staging, and treatment of cancer.
Saketh Guntupalli, MD, highlights data supporting PARP inhibitors as the standard-of-care frontline therapy, strategies for the management of PARP-related toxicities, and the importance of testing for HRD and BRCA status in patients with ovarian cancer.
Similar to first-line therapy choices, particular treatment factors, including type and duration of response to prior therapy, pace of disease progression, and toxicities associated with first-line treatment, are all practical considerations that help guide therapy selection in metastatic renal cell carcinoma.
Tusamitamab ravtansine, an antibody-drug conjugate that targets CEACAM5, could expand the treatment armamentarium for patients with CEACAM5-positive nonsquamous non–small cell lung cancer.
The addition of daratumumab to lenalidomide and dexamethasone led to a 27% reduction in the risk of death compared with Rd alone in patients with relapsed/refractory multiple myeloma.
Neoadjuvant treatment with anti–PD-1 inhibitors induced high rates of complete response and reduced recurrence rates, according to a retrospective analysis of patients with localized mismatch repair-deficient or microsatellite instability–high colorectal cancer.
The FDA has granted an orphan drug designation to JBI-802 for the treatment of patients with small cell lung cancer and acute myeloid leukemia.
Press Release
New research including Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis indicates it’s both possible and helpful to get cancer patients who smoke into evidence-based tobacco-treatment programs as part of their cancer care.
R-DHAP plus high-dose cytarabine-containing myeloablative radiochemotherapy conditioning and autologous stem cell transplant demonstrated sustained time to treatment failure and overall survival benefits vs R-CHOP plus standard myeloablative radiochemotherapy and ASCT in patients with mantle cell lymphoma aged 65 years and younger.
Efforts to target the folate metabolism network have entered a new stage, with the approval of a novel therapy directed at folate receptor–α and the potential for additional agents aimed at that target in solid tumors.
Axicabtagene ciloleucel continued to elicit improved progression-free survival and overall response rates in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Patients with B-cell malignancies who were intolerant to acalabrutinib experienced a longer treatment duration when subsequently receiving zanubrutinib.
First-line treatment with zanubrutinib plus rituximab followed by short-course rituximab plus dexamethasone, high-dose cytarabine, and oxaliplatin elicited responses in patients with mantle cell lymphoma, according to preliminary results from the phase 2 CHESS trial.
A doublet comprised of the bispecific innate cell engager AFM24 and atezolizumab had a tolerable safety profile and elicited responses in patients with advanced EGFR-expressing solid tumors.
Emma Searle, PhD, provides an overview of findings from the MajesTEC-2 trial in patients with relapsed/refractory multiple myeloma, elaborates on the safety of teclistamab plus daratumumab and lenalidomide, and discusses the next steps for evaluating the combination.
The use of peptide receptor radionuclide therapy with lutetium Lu 177 dotatate improved progression-free survival in patients with unresectable, progressive neuroendocrine pancreatic tumors.
Gopa Iyer, MD, explained the rarity of TSC1 and TSC2 mutations in GU cancers, discussed the rationale and design of PRECISION 1, and emphasized the important role next-generation sequencing plays when determining the most effective targeted therapies for patients with GU cancers and other tumor types.
Press Release
Fox Chase Cancer Center is pleased to announce the hiring of Lindsey B. Taylor, MD, as an assistant professor in the Department of Hematology/Oncology and the Breast Cancer and Hematology Programs.
Moxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.
Leading experts in the field of liver cancer contextualized how recent data are influencing the treatment paradigm in hepatocellular carcinoma.
Treatment with brexucabtagene autoleucel produced ongoing responses in patients with mantle cell lymphoma with high-risk disease characteristics, including those with a lower ECOG performance score and tumor burden and less frequent prior use of bridging or platinum therapy.
ADXS-504, an investigational off-the-shelf neoantigen therapy, has been reported to be well tolerated and safe in patients with biochemically recurrent early prostate cancer.
The utilization of the anti-CD40 agonist, CDX-1140, in combination with pembrolizumab was generally well tolerated and demonstrated preliminary efficacy in patients with anti–PD-1/PD-L1 resistant, locally advanced or metastatic solid tumors.
Results from a study of 318,549 Medicare beneficiaries with poor-prognosis cancers showed than Black and Hispanic patients were substantially less likely to receive any opioids or long-acting opioids than White patients at the end of life.
Long-serving pharmacy executive, Ray Bailey, retired on December 31, 2022.
The FDA has granted an orphan drug designation to QN-302 for the treatment of patients with pancreatic cancer.
because of the differences between the characteristics of research subjects and individuals routinely cared for outside the confines of a clinical trial, appropriately designed examinations of “real-world” populations may provide a more relevant picture of the actual influence of a particular therapeutic intervention.
